154 related articles for article (PubMed ID: 19834783)
1. Thrombolytic efficacy of recombinant human microplasmin in a canine model of copper coil-induced coronary artery thrombosis.
Dommke C; Turschner O; Stassen JM; Van de Werf F; Lijnen HR; Verhamme P
J Thromb Thrombolysis; 2010 Jul; 30(1):46-54. PubMed ID: 19834783
[TBL] [Abstract][Full Text] [Related]
2. Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
Rapold HJ; Wu ZM; Stassen T; Van de Werf F; Collen D
Blood; 1990 Oct; 76(8):1558-63. PubMed ID: 2119830
[TBL] [Abstract][Full Text] [Related]
3. Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion.
Longridge DJ; Follenfant MJ; Ford AJ
Cardiovasc Res; 1991 Mar; 25(3):184-91. PubMed ID: 1903080
[TBL] [Abstract][Full Text] [Related]
4. A novel human microplasmin fold: new perspective to thrombosis treatment.
Joison AN; Gallo FS
Blood Coagul Fibrinolysis; 2011 Apr; 22(3):236-9. PubMed ID: 21245749
[TBL] [Abstract][Full Text] [Related]
5. Neutralization of alpha(2)-antiplasmin by microplasmin: a randomized, double-blind, placebo-controlled, ascending-dose study in healthy male volunteers.
Pakola S; Cahillane G; Stassen JM; Lijnen HR; Verhamme P
Clin Ther; 2009 Aug; 31(8):1688-706. PubMed ID: 19808128
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human microplasmin: production and potential therapeutic properties.
Nagai N; Demarsin E; Van Hoef B; Wouters S; Cingolani D; Laroche Y; Collen D
J Thromb Haemost; 2003 Feb; 1(2):307-13. PubMed ID: 12871505
[TBL] [Abstract][Full Text] [Related]
7. A targeted ferritin-microplasmin based thrombolytic nanocage selectively dissolves blood clots.
Seo J; Al-Hilal TA; Jee JG; Kim YL; Kim HJ; Lee BH; Kim S; Kim IS
Nanomedicine; 2018 Apr; 14(3):633-642. PubMed ID: 29309907
[TBL] [Abstract][Full Text] [Related]
8. Effects of microplasmin on recovery in a rat embolic stroke model.
Rasmussen RS; Overgaard K; Pakola S; Boysen G
Neurol Res; 2008 Feb; 30(1):75-81. PubMed ID: 17588313
[TBL] [Abstract][Full Text] [Related]
9. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
[TBL] [Abstract][Full Text] [Related]
10. Catheter-directed thrombolysis with microplasmin for acute peripheral arterial occlusion (PAO): an exploratory study.
Verhamme P; Heye S; Peerlinck K; Cahillane G; Tangelder M; Fourneau I; Daenens K; Belmans A; Pakola S; Verhaeghe R; Maleux G
Int Angiol; 2012 Jun; 31(3):289-96. PubMed ID: 22634985
[TBL] [Abstract][Full Text] [Related]
11. Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi.
Suzuki S; Saito M; Suzuki N; Kato H; Nagaoka N; Yoshitake S; Mizuo H; Yuzuriha T; Yui Y; Kawai C
J Cardiovasc Pharmacol; 1991 May; 17(5):738-46. PubMed ID: 1713988
[TBL] [Abstract][Full Text] [Related]
12. Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits.
Lapchak PA; Araujo DM; Pakola S; Song D; Wei J; Zivin JA
Stroke; 2002 Sep; 33(9):2279-84. PubMed ID: 12215599
[TBL] [Abstract][Full Text] [Related]
13. Microplasmin-assisted vitrectomy.
Gandorfer A
Dev Ophthalmol; 2009; 44():26-30. PubMed ID: 19494649
[TBL] [Abstract][Full Text] [Related]
14. An increase in low aortic pressure increases coronary artery flow and coronary thrombolysis induced by intravenous administration of recombinant tissue plasminogen activator.
Garber PJ; Gu S; Ducas J; Schick U; Prewitt RM
J Crit Care; 1995 Mar; 10(1):1-6. PubMed ID: 7757138
[TBL] [Abstract][Full Text] [Related]
15. Comparative studies of thrombolysis with single-chain and two-chain recombinant tissue-type plasminogen activators in canine coronary thrombosis.
Yokoyama M; Ichikawa Y; Yatani A; Matsui K; Nakahara H; Kaneko M; Sakurama T; Ueshima S; Matsuo O
J Cardiovasc Pharmacol; 1996 Oct; 28(4):571-5. PubMed ID: 8891884
[TBL] [Abstract][Full Text] [Related]
16. Randomized, placebo-controlled, dose-ranging clinical trial of intravenous microplasmin in patients with acute ischemic stroke.
Thijs VN; Peeters A; Vosko M; Aichner F; Schellinger PD; Schneider D; Neumann-Haefelin T; Röther J; Davalos A; Wahlgren N; Verhamme P
Stroke; 2009 Dec; 40(12):3789-95. PubMed ID: 19834019
[TBL] [Abstract][Full Text] [Related]
17. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis.
Martin U; Fischer S; Sponer G
J Am Coll Cardiol; 1993 Sep; 22(3):914-20. PubMed ID: 8354832
[TBL] [Abstract][Full Text] [Related]
18. Retrograde coronary venous administration of recombinant tissue-type plasminogen activator: a unique and effective approach to coronary artery thrombolysis.
Miyazaki A; Tadokoro H; Drury JK; Rydén L; Haendchen RV; Corday E
J Am Coll Cardiol; 1991 Aug; 18(2):613-20. PubMed ID: 1906906
[TBL] [Abstract][Full Text] [Related]
19. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial.
Thiele H; Schindler K; Friedenberger J; Eitel I; Fürnau G; Grebe E; Erbs S; Linke A; Möbius-Winkler S; Kivelitz D; Schuler G
Circulation; 2008 Jul; 118(1):49-57. PubMed ID: 18559698
[TBL] [Abstract][Full Text] [Related]
20. Intravenous administration of recombinant tissue plasminogen activator. Optimizing the rate of coronary thrombolysis.
Prewitt RM; Gu S; Schick U; Ducas J
Chest; 1995 Apr; 107(4):1146-51. PubMed ID: 7705128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
